Sign in
Stories
EnteroBiotix Secures €31.4M Funding for Microbial Therapeutics
Share
Australia's Probiotics Market Growth
Growing Prebiotics and Probiotics Market...
COVID-19 Induces Brain Fog & IQ Drop
EnteroBiotix Strengthens Executive Team ...
Prebiotics Market Booming: $24 Billion b...
Overview
API
EnteroBiotix, a biotech firm in Glasgow, secures €31.4M funding to advance microbial therapies for IBS and liver cirrhosis.
Ask a question
How might this funding impact the availability and effectiveness of treatments for IBS and liver cirrhosis?
In what ways could advancements in microbial therapeutics influence the broader landscape of healthcare innovation?
What challenges and opportunities could EnteroBiotix face in developing microbiome therapies?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Jan 2024
Feb 2024
Mar 2024
Coverage